Douglas Hay, Project Leader
Douglas Hay is a pharmaceutical executive with more than 20 years of experience in drug discovery with GlaxoSmithKline. Dr. Hay has particular experience in respiratory and inflammatory disease therapeutics and was most recently Vice President of the COPD Drug Discovery group within the Respiratory & Inflammation Centre of Excellence for Drug Discovery.
Dr. Hay received his PhD in Physiology and Pharmacology from the University of Strathclyde, Scotland.
Christa Pawlowski, Project Operations Director
Christa Pawlowski has 10 years of research experience related to life sciences and drug development. While focused on cardiovascular disorders, her experience also includes inflammation, immune response and cancer. Prior to joining Allinaire, Dr. Pawlowski was a Postdoctoral Scholar at Case Western Reserve University and co-founder of Haima Therapeutics LLC, a biotechnology company focused on the translation of a novel synthetic platelet nanotechnology for the treatment of hemorrhage after traumatic injury.
Dr. Pawlowski received her PhD in Biomedical Engineering from Case Western Reserve University
Wade Lange, Founder & Senior Adviser
Wade Lange is an experienced biotech entrepreneur having spent over 30 years in the pharmaceutical industry. Starting his career in new product planning and market research at Lilly, Mr. Lange has over 10 years of experience leading university start-ups as CEO including ImmuneWorks, a pulmonary disease focused company which has progressed into the clinical trial stage. He currently leads NeuroFx, a regenerative medicine startup focused on treatment of neurological disorders.
Mr. Lange received his Pharmacy and Industrial Administration degrees from Purdue University.